April 23, 2021 11:18 AM EDT
News Briefing

J&J's Trem­fya scores 5-year pso­ri­a­sis win in AAD da­ta dump; Roche, Re­gen­eron drugs among lat­est to earn EU ad­vi­so­ry group's nod

Josh Sullivan

Max Gelman

Senior Editor

Kyle Blankenship

In the heat­ed pso­ri­a­sis mar­ket, every play­er is look­ing for a leg up. Now, J&J has long-term ef­fi­ca­cy da­ta show­ing pos­i­tive re­sults for Trem­fya af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times